DSG-Ⅰ型生物信息红外肝病治疗仪治疗大鼠非酒精性脂肪肝  

Experimental study on nonalcoholic fatty liver disease treated by medical instrument on hepatic diseases of type Ⅰ DSG in rats

作　　者：窦爱霞[1] 宗蕾[1] 周琨[1] 陈婷[1] 潘浩[1] 张权[1] 李继强[1] 房静远[1] 陆伦根[1] 

机构地区：[1]上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所,上海市200001

出　　处：《世界华人消化杂志》2008年第9期935-940,共6页World Chinese Journal of Digestology

基　　金：上海市科学技术委员会资助项目;No.054119618;上海市重点学科建设资助项目;No.Y0205~~

摘　　要：目的:观察DSG-Ⅰ型生物信息红外肝病治疗仪治疗大鼠非酒精性脂肪性肝病的疗效.方法:♂SD大鼠50只随机分组,正常对照组20只喂饲普通饲料,模型对照组及近红外光治疗组共30只喂饲高脂饲料(0.88标准普通饲料+0.10猪油+0.02胆固醇).治疗组自13 wk始进行近红外线照射治疗,于20 wk结束治疗并处死各组大鼠,测定血清ALT、AST、GGT、ALP、TP、TG、TC、LDL和HDL水平,同时观察肝组织学改变.结果:20 wk实验结束时,与正常对照组相比,模型对照组肝指数(t=8.65,P<0.01)、血清ALT(t=4.65,P<0.01)、AST(t=4.74,P<0.01)、ALP(t=3.56,P<0.01)、TP(t=6.35,P<0.01)、TC(t=8.41,P<0.01)和LDL(t=8.86,P<0.01)水平显著升高;肝组织脂肪变性(Z= -4.135,P<0.01)、炎症(Z=-3.752,P<0.01)及纤维化程度(Z=-4.156,P<0.01)均较对照组程度重.与模型对照组相比,近红外光治疗组肝指数、血清ALT、GGT、ALP、TP、TG和TC水平均有所下降,但无统计学意义,而AST有明显降低(t=-2.404,P<0.05);肝组织脂肪变及炎症程度较模型组轻,但无统计学意义,而肝纤维化程度较模型组减轻(Z=-3.101,P<0.01).结论:DSG-Ⅰ型生物信息红外肝病治疗仪对大鼠高脂饮食非酒精性脂肪性肝病有一定的治疗作用.AIM： To investigate the primary therapeutic efficacy of the medical instrument on hepatic diseases of type Ⅰ DSG in treating nonalcoholic fatty liver disease （NAFLD） of rats. METHODS： Fifty male SD rats were randomly divided into 5 groups. The control groups （n = 20, N1 and N2 group） were fed with normal diet, and the model groups （n = 30, M1, M2 and T group） were fed with fat-rich diet consisting of 0.88 standard normal diet ＋ 0.10 lard oil ＋ 0.02cholesterol. Therapeutic group （T group） was treated from wk 13 and finished at wk 20. The levels of serum alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, gamma-glu- tamyl-transpeptidase （GGT）, alkaline phosphatase （ALP）, total protein （TP）, triglycerides （TG）, total cholesterol （TC）, low-density lipoprotein （LDL）, and high density lipoprotein （HDL） were measured. The hepatic histologic changes were observed with HE and Masson staining. RESULTS： At the end of the experiment, compared with those in the normal control groups, the liver index （t = 8.65, P 〈 0.01） and serum ALT （t = 4.65, P 〈 0.01）, AST （t = 4.74, P 〈 0.01）, ALP （t = 3.56, P 〈 0.01）, TP （t = 6.35, P 〈 0.01）, TC （t = 8.41, P 〈 0.01）, and LDL （t = 8.86, P 〈 0.01） levels were increased significantly in the model control groups, and the hepatic steatosis （Z = -4.135, P 〈 0.01）, inflammation （Z = -3.752, P 〈 0.01） and fibrosis （Z = -4.156, P 〈 0.01） were more serious. Compared with those in the model control groups, the serum ALT, GGT, ALP, TP, TG, and TC levels were all down-regulated in the therapeutic group without significances, while AST （t = -2.404, P 〈 0.05） level was reduced significantly. The degrees of hepatic steatosis and inflammation were decreased without statistical significances, but fibrosis degrees were lightened markedly （Z = -3.101, P 〈 0.01）. CONCLUSION： The medical instrument on hepatic diseases of type Ⅰ DSG has some therapeutic e

关 键 词：非酒精性脂肪性肝病 DSG-Ⅰ型生物信息 红外肝病治疗仪 大鼠 

分 类 号：R575.5[医药卫生—消化系统] R745.12[医药卫生—内科学]